Unknown

Dataset Information

Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysis.


ABSTRACT:

Introduction

The APLICOV-PC study assessed the safety and preliminary efficacy of plitidepsin in hospitalized adult patients with COVID-19. In this follow-up study (E-APLICOV), the incidence of post-COVID-19 morbidity was evaluated and any long-term complications were characterized.

Methods

Between January 18 and March 16, 2022, 34 of the 45 adult patients who received therapy with plitidepsin in the APLICOV-PC study were enrolled in E-APLICOV (median time from plitidepsin first dose to E-APLICOV enrollment, 16.8 months [range, 15.2-19.5 months]). All patients were functionally autonomous with regard to daily living (Barthel index: 100) and had normal physical examinations.

Results

From the APLICOV-PC date of discharge to the date of the extension visit, neither Commo

SUBMITTER: Varona JF 

PROVIDER: S-EPMC9992643 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature